Skip to search formSkip to main contentSkip to account menu

CC-223

Known as: TORKi, mTOR Kinase Inhibitor CC-223 
An orally available inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor CC-223… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Pyrazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Assessment of drug–drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase
Abstract 1. CC-223 was studied in vitro for metabolism and drug–drug interactions (DDI), and in clinic for interaction with… 
2018
2018
CC-223 inhibits human head and neck squamous cell carcinoma cell growth.
2016
2016
Phase I trial of a dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers.
2505Background: CC-115 is a potent inhibitor of DNA-PK and TOR kinase (DNA-PKi/TORKi) with broad pre-clinical anti-tumor activity… 
2015
2015
Abstract 1755: TORK/DNA-PK inhibitor CC-115 is effective as a single agent in a subset of glioblastoma patient-derived cancer stem cells and xenografts and potentiates temozolomide therapy
Glioblastoma (GBM) cells are highly invasive and respond poorly to radiation and chemotherapy. The mammalian target of rapamycin… 
2013
2013
Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in nonpancreatic neuroendocrine tumors (NET).
e15004 Background: Clinical activity of everolimus, an allosteric TORC1-selective inhibitor, has been established in pancreatic… 
2013
2013
Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM)
8522 Background: CC-223 is an ATP-competitive inhibitor of the mTOR kinase, including both TORC1 and TORC2 complexes. CC-223 was… 
2013
2013
Abstract 5252: CC-223, a selective and potent mTOR kinase inhibitor, synergizes with 5-Aza and Erlotinib in eight NSCLC lines in vitro.
CC-223 is a potent and selective mTOR kinase inhibitor currently undergoing Phase 1 clinical evaluation. We evaluated… 
2012
2012
Phase I trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid and hematologic cancers.
3006^ Background: The mammalian target of rapamycin (mTOR) signaling pathway is frequently activated in cancer. The mTOR kinase… 
2011
2011
Simulation Model for a Nomadic Animal Production System in
The first motive for the determination and evaluation of an energy production system is the need to change. Such system is… 
2011
2011
Notes on the natural history and distribution of Carinatogecko stevenandersoni Torki, 2011
—Carinatogecko Golubev and Szczerbak, 1981 comprises three species: C. aspratilis (Anderson 1973), distributed in Iran, C… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)